SELLAS Life Sciences (SLS) Operating Leases (2019 - 2026)
SELLAS Life Sciences (SLS) reported Operating Leases of $871000.0 for Q1 2026, up 181.88% year-over-year from $309000.0 in Q1 2025, and up 90.59% quarter-over-quarter from $457000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Operating Leases (2019 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 8 years of Operating Leases data on file, last reported at $871000.0 in Q1 2026.
- Operating Leases for Q1 2026 came in at $871000.0, up 181.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $871000.0 (up 181.88% YoY), and the FY2025 annual result was $457000.0, changed 0.0% from the prior year.
- Operating Leases advanced to $871000.0 in Q1 2026 per SLS's latest filing, from $457000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $1.2 million in Q1 2022 and troughed at $157000.0 in Q2 2025.
- A 5-year average of $600400.0 and a median of $460000.0 in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2026: Operating Leases tumbled 82.82% in 2023, then jumped 181.88% in 2026.
- A 5-year view of Operating Leases shows it stood at $573000.0 in 2022, then dropped by 19.72% to $460000.0 in 2023, then declined by 0.65% to $457000.0 in 2024, then changed by 0.0% to $457000.0 in 2025, then surged by 90.59% to $871000.0 in 2026.
- Business Quant data shows SLS's Operating Leases at $871000.0 in Q1 2026, $457000.0 in Q4 2025, and $157000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 871,000.00 |
| Dec 31, 2025 | 457,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Mar 31, 2025 | 309,000.00 |
| Dec 31, 2024 | 457,000.00 |
| Jun 30, 2024 | 692,000.00 |
| Mar 31, 2024 | 313,000.00 |
| Dec 31, 2023 | 460,000.00 |
| Sep 30, 2023 | 178,000.00 |
| Jun 30, 2023 | 749,000.00 |
| Mar 31, 2023 | 422,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 610,000.00 |
| Sep 30, 2021 | 667,000.00 |
| Jun 30, 2021 | 903,000.00 |
| Mar 31, 2021 | 775,000.00 |
| Dec 31, 2020 | 825,000.00 |